Baird analyst Evan Stover raised the firm’s price target on Catalent (CTLT) to $82 from $75 and keeps an Outperform rating on the shares. The analyst said they provided a mixed bag update, though good vibes win out largely due to the Moderna (MRNA) extension and expansion beyond COVID.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTLT: